Brivaracetam is a therapeutic alternative that allows savings for the health system in patients with non-controlled epilepsy in monotherapy, having a fixed, predictable annual cost (independent of dose) from the first day of treatment as the lack of need for titration means the patient is within a range of therapeutic doses from the first dose.

In the original publication, the abstract, conclusion was incorrectly published.Abstract, Conclusions which previously read: Brivaracetam is a therapeutic alternative that allows savings for the health system in patients with non-controlled epilepsy when used as monotherapy, having a fixed, predictable annual cost (independent of dose) from the first day of treatment as the lack of need for titration means the patient is within a range of therapeutic doses from the first dose. Should read:Brivaracetam is a therapeutic alternative that allows savings for the health system in patients with non-controlled epilepsy in monotherapy, having a fixed, predictable annual cost (independent of dose) from the first day of treatment as the lack of need for titration means the patient is within a range of therapeutic doses from the first dose.The original article was corrected.The original article can be found online at https://doi.org/10.1007/ s40261-017-0615-z.& Isabel Barrachina-Martínez